Astellas Pharma (ALPMF) Financial Statements

Compare

56 Followers

Astellas Pharma Financial Overview

Astellas Pharma's market cap is currently $28.61B. The company's EPS TTM is $0.35153892; its P/E ratio is 9.34; and it has a dividend yield of 3.75%. Astellas Pharma is scheduled to report earnings on February 4, 2026, and the estimated EPS forecast is $0.17. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Income Statement
Total Revenue	¥ 1.91T	¥ 1.60T	¥ 1.52T	¥ 1.30T	¥ 1.25T
Gross Profit	¥ 1.56T	¥ 1.31T	¥ 1.23T	¥ 1.04T	¥ 1.00T
Operating Income	¥ 255.67B	¥ 178.07B	¥ 285.43B	¥ 220.02B	¥ 250.90B
EBITDA	¥ 462.67B	¥ 282.45B	¥ 337.39B	¥ 297.83B	¥ 323.58B
Net Income	¥ 50.75B	¥ 17.05B	¥ 98.71B	¥ 124.09B	¥ 120.59B
Balance Sheet
Cash & Short-Term Investments	¥ 188.37B	¥ 335.69B	¥ 376.84B	¥ 315.99B	¥ 326.13B
Total Assets	¥ 3.34T	¥ 3.57T	¥ 2.46T	¥ 2.33T	¥ 2.27T
Total Debt	¥ 937.09B	¥ 1.01T	¥ 200.01B	¥ 212.74B	¥ 278.26B
Net Debt	¥ 748.71B	¥ 670.03B	¥ -176.83B	¥ -103.24B	¥ -47.86B
Total Liabilities	¥ 1.83T	¥ 1.97T	¥ 948.56B	¥ 872.09B	¥ 887.51B
Stockholders' Equity	¥ 1.51T	¥ 1.60T	¥ 1.51T	¥ 1.46T	¥ 1.39T
Cash Flow
Free Cash Flow	¥ 164.61B	¥ 143.27B	¥ 295.88B	¥ 227.42B	¥ 276.50B
Operating Cash Flow	¥ 201.61B	¥ 181.32B	¥ 332.32B	¥ 258.16B	¥ 307.88B
Investing Cash Flow	¥ -96.52B	¥ -854.65B	¥ -89.06B	¥ -63.13B	¥ -82.93B
Financing Cash Flow	¥ -261.37B	¥ 614.06B	¥ -195.62B	¥ -216.30B	¥ -229.48B

Currency in JPY

Astellas Pharma Earnings and Revenue History

Income Statement >

Astellas Pharma Debt to Assets

Balance Sheet >

Astellas Pharma Cash Flow

Cash Flow >

Astellas Pharma Forecast EPS vs Actual EPS

Earnings >